Get started
Work

Pooled Analysis of Day +100 Survival for Defibrotide-Treated Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) and Ventilator or Dialysis Dependence Following Hematopoietic Stem Cell Transplantation (HSCT)

Year: 2018
Type: article
Abstract: Background: VOD/SOS is an unpredictable complication of conditioning for HSCT or chemotherapy. VOD/SOS with multi-organ dysfunction (MOD) may be associated with >80% mortality. In the US, defibrotide is approved to treat hepatic VOD/SOS with renal or pulmonary dysfunction after HSCT; it is approved in the EU to treat severe hepatic VOD/SOS after HSCT in patients aged >1 month. Here, a pooled analysis evaluated Day +100 survival by severity of MOD.
DOI: 10.1016/j.bbmt.2017.12.367
Authors: Paul G. Richardson, Angela R. Smith, Nancy A. Kernan, Joseph H. Antin, Leslie Lehmann, Robert Ryan, Robin Hume, William Tappe, Stephan A. Grupp
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of Minnesota, Memorial Sloan Kettering Cancer Center, Jazz Pharmaceuticals (United States), Children's Hospital of Philadelphia
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2792461494
FWCI:
Cites:
Cited by:
Related to: 10